INCYTE
8.11.2016 14:03:30 CET | Business Wire | Press release
Incyte Biosciences International Sàrl, a European subsidiary of Incyte Corporation, and GENESIS Pharma S.A., a leading Greek pharmaceutical company, today announced that Incyte has granted GENESIS Pharma exclusive rights to commercialize Iclusig® (ponatinib) in Greece. Under the terms of the agreement, GENESIS Pharma will be responsible for sales and marketing, medical affairs, and regulatory and reimbursement support for Iclusig in Greece.
“The agreement with GENESIS Pharma will expand the availability of Iclusig to patients in geographies beyond our current European footprint,” said Jonathan Dickinson, Incyte’s General Manager, Europe. “We look forward to collaborating with GENESIS Pharma, whose oncology and hematology experience makes them an ideal partner to enable patient and physician access to Iclusig in Greece.”
In Europe and other select ex-U.S. countries, Iclusig is approved for the treatment of adult patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to specific second generation tyrosine kinase inhibitor (TKIs); or who have the T315I mutation.
“We are very happy to announce our partnership with Incyte. For us, it is another step forward to delivering our mission to provide innovative hematology treatments to patients in Greece,” said Constantinos Evripides, Chief Executive Officer of GENESIS Pharma. “Once available, Iclusig will add to the broad portfolio of treatments for patients with rare and difficult to treat hematological diseases that GENESIS Pharma commercializes in Greece. We are very pleased to have another leading international pharmaceutical company, like Incyte, recognize our expertise and high quality standards, and place its trust in us.”
According to the European Medicines Agency’s orphan drug designation1 and the HAEMACARE project2 , there are approximately 1,000 CML and Ph+ ALL patients in Greece.
GENESIS Pharma has submitted a pricing application for Iclusig in Greece; the application is currently under review by the Greek Ministry of Health. Pending their approval, the commercial launch of Iclusig is expected to occur in the first half of 2017.
About Iclusig ® (ponatinib) tablets
Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.
In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or for the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Incyte has an exclusive license from ARIAD Pharmaceuticals, Inc. to develop and commercialize Iclusig in the European Union and 28 other countries, including Switzerland, Norway, Iceland, Turkey, Israel and Russia.
Iclusig® is a registered trademark of ARIAD Pharmaceuticals, Inc.
About Incyte
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Headquartered in Wilmington, Delaware, Incyte also has offices in Switzerland and nine other European countries. For additional information on Incyte, please visit the Company’s website at www.incyte.com .
Follow @Incyte on Twitter at https://twitter.com/Incyte .
About GENESIS Pharma
GENESIS Pharma was among the first pharmaceutical companies in Europe specialized in biopharmaceutical products and is currently the largest among Greek companies specializing in branded innovative medicines, mainly in the therapeutic areas of Oncology, Hematology, CNS, Gastroenterology and Nephrology. The company has created a strong product portfolio that includes high-tech pharmaceutical products for severe and rare diseases, through long standing strategic alliances for the broader region of Southeast Europe with some of the leading multinational pharmaceutical companies committed to cutting edge R&D.
For further information please visit www.genesispharma.com .
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether the collaboration with GENESIS Pharma will be successful in expanding access for patients in Greece to Iclusig; whether the Greek Ministry of Health will approve the pricing application for Iclusig; and the expected timing of the commercial launch of Iclusig in Greece. These forward-looking statements are based on the Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks detailed from time to time in the Incyte’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2016. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Public summary of opinion on orphan designation, Committee for Orphan Medicinal Products, European Medicines Agency, 2 March 2010, http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/03/WC500075158.pdf
2 Sant et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010 116:3724-3734
View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005603/en/
Contact:
Incyte Contacts
Media
Catalina Loveman
+1
302-498-6171
cloveman@incyte.com
or
Investors
Michael
Booth, DPhil
+1 302-498-5914
mbooth@incyte.com
or
GENESIS
Pharma Contact
Vicky Karra
Corporate Affairs Manager
+30
210 87 71 500
vkarra@genesispharma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danube Properties Expands UK Presence with New London Office, Eyes Wider European Growth3.6.2026 11:34:00 CEST | Press release
Danube Properties, one of the UAE’s leading real estate developers, is set to strengthen its international presence with the launch of its new sales office in Central London. Located at 44 Brompton Road, Knightsbridge, SW3 1BW, the new office marks another milestone in the company’s growing expansion across the United Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260530149191/en/ Atif Farid, Head Business Development (UK); Rizwan Sajan, Founder and Chairman of Danube Group; and Adel Sajan, Managing Director of Danube Group, at the launch of Danube Properties' new sales office in Central London. (Photo: AETOSWire) The opening follows the successful launch of Danube Properties’ first UK office in Harrow two years ago, which established a strong connection with investors and homebuyers seeking premium Dubai real estate opportunities. Building on this momentum, the new Knightsbridge office aims to provide enhanced acce
Sensofusion Introduces its Aerospace Unit: Swift Surveillance Aircraft and Fennec Satellites3.6.2026 11:30:00 CEST | Press release
Finnish defence technology company Sensofusion Oy is expanding its operations from the ground to the air and into Earth orbit. As of today, the company's aviation and space business will operate under the name Sensofusion Aerospace.The unit's ongoing product development projects are the Sensofusion Swift surveillance aircraft and the company's first two satellite missions, Fennec-1 and Fennec-2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603447178/en/ With the Fennec-satellite program, Sensofusion's sensing capability extends into Earth orbit. Sensofusion Swift is a type-certified general aviation aircraft with integrated signals intelligence capability, radar and other advanced sensors. Unlike unmanned systems, Swift can operate in peacetime airspace near airports and population centres without separate exemptions. Sensofusion Swift is both an aircraft and a drone. It can be procured and operated either as a crewed g
Swedish Court Reschedules Publication of Judgment in PriceRunner Vs Google Antitrust Case3.6.2026 10:34:00 CEST | Press release
Klarna provides investor update Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from 10 June to 26 June, 2026 at 11:00 CET. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klarna’s litigation funder, and to applicable taxation. The dollar amount of the claim should not be taken as an indication of any likely recovery. This announcement does not constitute a profit forecast. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable
Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 20143.6.2026 10:00:00 CEST | Press release
Illicit cigarettes reached 10.3% of EU consumption in 2025 (41.8 billion), with an estimated €16.7 billion in lost tax revenuesCounterfeits now lead the illicit market - accounting for 44% of EU illicit consumption (18.3 billion), up sharply year-on-year and displacing traditional East-to-West contraband flowsWestern Europe has the highest levels of illicit consumption, with France (41.4%), Belgium (24.8%), and the Netherlands (22.1%) among the most impacted. In France alone, counterfeit volumes reached nearly 10 billion cigarettes A new study detailing the scale of the illicit cigarette trade in the European Union (EU) shows that consumption of black-market cigarettes rose more than 7% year-on-year in 2025, reaching levels not seen in over a decade, with counterfeit cigarettes playing an increasingly significant role across member states. Philip Morris International (PMI) (NYSE: PM) reiterates its call for a coordinated response to illicit trade in Europe, built on evidence-based regu
Veth Propulsion by Twin Disc Unveiled New Streamline‑CRP™ at Maritime Industry Event3.6.2026 10:00:00 CEST | Press release
Product Reveal Took Place on June 2 Veth Propulsion by Twin Disc, a global leader in marine propulsion and maneuvering solutions, unveiled a new addition to its portfolio at Maritime Industry, a leading inland shipping tradeshow in the Netherlands, on June 2. Attendees experienced the debut firsthand. The new product, Streamline‑CRP™, is a major step forward in contra‑rotating propulsion technology. It was developed to meet the demand for higher efficiency, reduced emissions and better onboard comfort. It is purpose‑built for passenger cruise vessels and ferries. Streamline‑CRP delivers superior hydrodynamic performance, even in demanding, shallow‑water conditions. Streamline‑CRP is a next-generation azimuth thruster. It builds on Veth Propulsion’s long experience designing and making advanced propulsion systems. “Customers across the marine industry are demanding solutions that deliver both performance and efficiency,” said Bastiaan van Zuijlekom, Managing Director of Veth Propulsion.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom